Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 138

1.

Survival in patients with malignant pleural effusion undergoing talc pleurodesis.

Hassan M, Mercer RM, Maskell NA, Asciak R, McCracken DJ, Bedawi EO, Shaarawy H, El-Ganady A, Psallidas I, Miller RF, Rahman NM.

Lung Cancer. 2019 Nov;137:14-18. doi: 10.1016/j.lungcan.2019.09.003. Epub 2019 Sep 4.

PMID:
31521977
2.

Inter-observer variation in image interpretation and the prognostic importance of non-expansile lung in malignant pleural effusion.

Martin GA, Kidd AC, Tsim S, Halford P, Bibby A, Maskell NA, Blyth KG.

Respirology. 2019 Aug 21. doi: 10.1111/resp.13681. [Epub ahead of print]

PMID:
31433545
3.

Epstein-Barr virus in pleural effusions: protagonist or pretender?

Arnold DT, Suri T, Hamilton F, Morley A, Medford A, Vipond IB, Muir P, Maskell NA.

Eur Respir J. 2019 Oct 31;54(4). pii: 1900825. doi: 10.1183/13993003.00825-2019. Print 2019 Oct. No abstract available.

PMID:
31248955
4.

Primary spontaneous pneumothorax: time for surgery at first episode?

Cardillo G, Ricciardi S, Rahman N, Walker S, Maskell NA.

J Thorac Dis. 2019 May;11(Suppl 9):S1393-S1397. doi: 10.21037/jtd.2019.03.22. No abstract available.

5.

The Prevalence and Clinical Relevance of Nonexpandable Lung in Malignant Pleural Mesothelioma. A Prospective, Single-Center Cohort Study of 229 Patients.

Bibby AC, Halford P, De Fonseka D, Morley AJ, Smith S, Maskell NA.

Ann Am Thorac Soc. 2019 Oct;16(10):1273-1279. doi: 10.1513/AnnalsATS.201811-786OC.

PMID:
31189069
6.

Development of and Gathering Validity Evidence for a Theoretical Test in Thoracic Ultrasound.

Pietersen PI, Konge L, Madsen KR, Bendixen M, Maskell NA, Rahman N, Graumann O, Laursen CB.

Respiration. 2019;98(3):221-229. doi: 10.1159/000500146. Epub 2019 May 28.

PMID:
31137031
7.

Cost-effectiveness of intrapleural use of tissue plasminogen activator and DNase in pleural infection: evidence from the MIST2 randomised controlled trial.

Luengo-Fernandez R, Penz E, Dobson M, Psallidas I, Nunn AJ, Maskell NA, Rahman NM.

Eur Respir J. 2019 Aug 1;54(2). pii: 1801550. doi: 10.1183/13993003.01550-2018. Print 2019 Aug.

PMID:
31097519
8.

Relationship of pleural fluid pH and glucose: a multi-centre study of 2,971 cases.

Fitzgerald DB, Leong SL, Budgeon CA, Murray K, Rosenstengal A, Smith NA, Bielsa S, Clive AO, Maskell NA, Porcel JM, Lee YCG.

J Thorac Dis. 2019 Jan;11(1):123-130. doi: 10.21037/jtd.2018.12.101.

9.

Is pleural infection associated with longer survival in mesothelioma? A population-based cohort study using data from Hospital Episode Statistics.

Bibby AC, de Fonseka D, Carslake DJ, Maskell NA.

Cancer Epidemiol. 2019 Apr;59:75-82. doi: 10.1016/j.canep.2019.01.014. Epub 2019 Jan 30.

10.

MesoTRAP: a feasibility study that includes a pilot clinical trial comparing video-assisted thoracoscopic partial pleurectomy decortication with indwelling pleural catheter in patients with trapped lung due to malignant pleural mesothelioma designed to address recruitment and randomisation uncertainties and sample size requirements for a phase III trial.

Matthews C, Freeman C, Sharples LD, Fox-Rushby J, Tod A, Maskell NA, Edwards JG, Coonar AS, Sivasothy P, Hughes V, Rahman NM, Waller DA, Rintoul RC.

BMJ Open Respir Res. 2019 Jan 5;6(1):e000368. doi: 10.1136/bmjresp-2018-000368. eCollection 2019.

11.

Early specialist palliative care on quality of life for malignant pleural mesothelioma: a randomised controlled trial.

Brims F, Gunatilake S, Lawrie I, Marshall L, Fogg C, Qi C, Creech L, Holtom N, Killick S, Yung B, Cooper D, Stadon L, Cook P, Fuller E, Walther J, Plunkett C, Bates A, Mackinlay C, Tandon A, Maskell NA, Forbes K, Rahman NM, Gerry S, Chauhan AJ; RESPECT-Meso investigators.

Thorax. 2019 Apr;74(4):354-361. doi: 10.1136/thoraxjnl-2018-212380. Epub 2019 Jan 19.

PMID:
30661019
12.

Summary for Clinicians: Clinical Practice Guideline for Management of Malignant Pleural Effusions.

Reddy CB, DeCamp MM, Diekemper RL, Gould MK, Henry T, Iyer NP, Lee YCG, Lewis SZ, Maskell NA, Rahman NM, Sterman DH, Wahidi MM, Balekian AA, Feller-Kopman DJ.

Ann Am Thorac Soc. 2019 Jan;16(1):17-21. doi: 10.1513/AnnalsATS.201809-620CME. No abstract available.

PMID:
30516394
13.

Management of Malignant Pleural Effusions. An Official ATS/STS/STR Clinical Practice Guideline.

Feller-Kopman DJ, Reddy CB, DeCamp MM, Diekemper RL, Gould MK, Henry T, Iyer NP, Lee YCG, Lewis SZ, Maskell NA, Rahman NM, Sterman DH, Wahidi MM, Balekian AA.

Am J Respir Crit Care Med. 2018 Oct 1;198(7):839-849. doi: 10.1164/rccm.201807-1415ST.

PMID:
30272503
14.

Investigating unilateral pleural effusions: the role of cytology.

Arnold DT, De Fonseka D, Perry S, Morley A, Harvey JE, Medford A, Brett M, Maskell NA.

Eur Respir J. 2018 Nov 8;52(5). pii: 1801254. doi: 10.1183/13993003.01254-2018. Print 2018 Nov.

PMID:
30262573
15.

Local Anaesthetic (Medical) Thoracoscopy Services in the UK.

de Fonseka D, Bhatnagar R, Maskell NA.

Respiration. 2018;96(6):560-563. doi: 10.1159/000491674. Epub 2018 Sep 10.

PMID:
30199872
16.

Zoledronic acid in the management of mesothelioma - a feasibility study (Zol-A Trial): study protocol for a randomised controlled trial.

de Fonseka D, Morley A, Stadon L, Keenan E, Walker S, Smith S, Harvey JE, Cox RA, Dangoor A, Comins C, Rogers C, Edey A, Addeo A, Maskell NA.

Trials. 2018 Aug 29;19(1):467. doi: 10.1186/s13063-018-2851-9.

17.

Current treatments and trials in malignant pleural mesothelioma.

Bibby AC, Maskell NA.

Clin Respir J. 2018 Jul;12(7):2161-2169. doi: 10.1111/crj.12938. Review.

PMID:
30129116
18.

ERS/EACTS statement on the management of malignant pleural effusions.

Bibby AC, Dorn P, Psallidas I, Porcel JM, Janssen J, Froudarakis M, Subotic D, Astoul P, Licht P, Schmid R, Scherpereel A, Rahman NM, Maskell NA, Cardillo G.

Eur J Cardiothorac Surg. 2019 Jan 1;55(1):116-132. doi: 10.1093/ejcts/ezy258. Review.

PMID:
30060030
19.

ERS/EACTS statement on the management of malignant pleural effusions.

Bibby AC, Dorn P, Psallidas I, Porcel JM, Janssen J, Froudarakis M, Subotic D, Astoul P, Licht P, Schmid R, Scherpereel A, Rahman NM, Cardillo G, Maskell NA.

Eur Respir J. 2018 Jul 27;52(1). pii: 1800349. doi: 10.1183/13993003.00349-2018. Print 2018 Jul. Review.

PMID:
30054348
20.

Aggressive versus symptom-guided drainage of malignant pleural effusion via indwelling pleural catheters (AMPLE-2): an open-label randomised trial.

Muruganandan S, Azzopardi M, Fitzgerald DB, Shrestha R, Kwan BCH, Lam DCL, De Chaneet CC, Rashid Ali MRS, Yap E, Tobin CL, Garske LA, Nguyen PT, Stanley C, Popowicz ND, Kosky C, Thomas R, Read CA, Budgeon CA, Feller-Kopman D, Maskell NA, Murray K, Lee YCG.

Lancet Respir Med. 2018 Sep;6(9):671-680. doi: 10.1016/S2213-2600(18)30288-1. Epub 2018 Jul 20.

PMID:
30037711
21.

Are intra-pleural bacterial products associated with longer survival in adults with malignant pleural effusions? A systematic review.

Bibby AC, Walker S, Maskell NA.

Lung Cancer. 2018 Aug;122:249-256. doi: 10.1016/j.lungcan.2018.06.002. Epub 2018 Jun 11.

22.

Recurrence rates in primary spontaneous pneumothorax: a systematic review and meta-analysis.

Walker SP, Bibby AC, Halford P, Stadon L, White P, Maskell NA.

Eur Respir J. 2018 Sep 6;52(3). pii: 1800864. doi: 10.1183/13993003.00864-2018. Print 2018 Sep.

PMID:
30002105
23.

An Inconvenient Truth Concerning Surgery for Mesothelioma.

de Fonseka D, Slade M, Blyth KG, Edwards J, Evison M, Roberts M, Rahman N, Woolhouse I, Maskell NA.

J Clin Oncol. 2018 Sep 10;36(26):2745-2746. doi: 10.1200/JCO.2018.78.6590. Epub 2018 Jun 14. No abstract available.

PMID:
29902107
24.

Outpatient Talc Administration by Indwelling Pleural Catheter for Malignant Effusion.

Bhatnagar R, Keenan EK, Morley AJ, Kahan BC, Stanton AE, Haris M, Harrison RN, Mustafa RA, Bishop LJ, Ahmed L, West A, Holme J, Evison M, Munavvar M, Sivasothy P, Herre J, Cooper D, Roberts M, Guhan A, Hooper C, Walters J, Saba TS, Chakrabarti B, Gunatilake S, Psallidas I, Walker SP, Bibby AC, Smith S, Stadon LJ, Zahan-Evans NJ, Lee YCG, Harvey JE, Rahman NM, Miller RF, Maskell NA.

N Engl J Med. 2018 Apr 5;378(14):1313-1322. doi: 10.1056/NEJMoa1716883.

25.

Randomised controlled trial to compare the diagnostic yield of positron emission tomography CT (PET-CT) TARGETed pleural biopsy versus CT-guided pleural biopsy in suspected pleural malignancy (TARGET trial).

de Fonseka D, Underwood W, Stadon L, Rahman N, Edey A, Rogers C, Maskell NA.

BMJ Open Respir Res. 2018 Feb 19;5(1):e000270. doi: 10.1136/bmjresp-2017-000270. eCollection 2018.

26.

BTS guideline for the investigation and management of malignant pleural mesothelioma.

Woolhouse I, Bishop L, Darlison L, de Fonseka D, Edey A, Edwards J, Faivre-Finn C, Fennell DA, Holmes S, Kerr KM, Nakas A, Peel T, Rahman NM, Slade M, Steele J, Tsim S, Maskell NA.

BMJ Open Respir Res. 2018 Feb 14;5(1):e000266. doi: 10.1136/bmjresp-2017-000266. eCollection 2018.

27.

The role of procalcitonin in the management of pleural infection.

de Fonseka D, Maskell NA.

Curr Opin Pulm Med. 2018 Jul;24(4):380-383. doi: 10.1097/MCP.0000000000000481. Review.

PMID:
29528854
28.

A Pilot Feasibility Study in Establishing the Role of Ultrasound-Guided Pleural Biopsies in Pleural Infection (The AUDIO Study).

Psallidas I, Kanellakis NI, Bhatnagar R, Ravindran R, Yousuf A, Edey AJ, Mercer RM, Corcoran JP, Hallifax RJ, Asciak R, Shetty P, Dong T, Piotrowska HEG, Clelland C, Maskell NA, Rahman NM.

Chest. 2018 Oct;154(4):766-772. doi: 10.1016/j.chest.2018.02.031. Epub 2018 Mar 7.

PMID:
29524388
29.

A prospective study to investigate the role of serial serum mesothelin in monitoring mesothelioma.

de Fonseka D, Arnold DT, Stadon L, Morley A, Keenan E, Darby M, Armstrong L, Virgo P, Maskell NA.

BMC Cancer. 2018 Feb 17;18(1):199. doi: 10.1186/s12885-018-4113-3.

30.

Introducing the new BTS guideline: the investigation and management of pleural malignant mesothelioma.

Woolhouse I, Maskell NA.

Thorax. 2018 Mar;73(3):210-212. doi: 10.1136/thoraxjnl-2017-211416. No abstract available.

PMID:
29444989
31.

British Thoracic Society Guideline for the investigation and management of malignant pleural mesothelioma.

Woolhouse I, Bishop L, Darlison L, De Fonseka D, Edey A, Edwards J, Faivre-Finn C, Fennell DA, Holmes S, Kerr KM, Nakas A, Peel T, Rahman NM, Slade M, Steele J, Tsim S, Maskell NA.

Thorax. 2018 Mar;73(Suppl 1):i1-i30. doi: 10.1136/thoraxjnl-2017-211321. No abstract available.

PMID:
29444986
32.

Evaluating quality of life and cost implications of prophylactic radiotherapy in mesothelioma: Health economic analysis of the SMART trial.

Stewart SA, Clive AO, Maskell NA, Penz E.

PLoS One. 2018 Feb 5;13(2):e0190257. doi: 10.1371/journal.pone.0190257. eCollection 2018.

33.

Commentary: considerations for using the 'Trials within Cohorts' design in a clinical trial of an investigational medicinal product.

Bibby AC, Torgerson DJ, Leach S, Lewis-White H, Maskell NA.

Trials. 2018 Jan 8;19(1):18. doi: 10.1186/s13063-017-2432-3.

34.

18F-Fluorodeoxyglucose PET/CT and dynamic contrast-enhanced MRI as imaging biomarkers in malignant pleural mesothelioma.

Hall DO, Hooper CE, Searle J, Darby M, White P, Harvey JE, Braybrooke JP, Maskell NA, Masani V, Lyburn ID.

Nucl Med Commun. 2018 Feb;39(2):161-170. doi: 10.1097/MNM.0000000000000789.

PMID:
29300270
35.

Exploring the characteristics of patients with mesothelioma who chose active symptom control over chemotherapy as first-line treatment: a prospective, observational, single centre study.

Bibby AC, De Fonseka D, Morley AJ, Keenan E, Addeo A, Smith S, Edey AJ, Maskell NA.

BMC Palliat Care. 2017 Dec 8;16(1):71. doi: 10.1186/s12904-017-0255-3.

36.

A Prospective Study to Evaluate a Diagnostic Algorithm for the Use of Fluid Lymphocyte Subset Analysis in Undiagnosed Unilateral Pleural Effusions.

Dixon G, Bhatnagar R, Zahan-Evans N, Clive AO, Virgo PF, Brett MT, Otton SH, Medford ARL, Maskell NA.

Respiration. 2018;95(2):98-105. doi: 10.1159/000481290. Epub 2017 Nov 10.

37.

Benign pleural schwannoma presenting with a large, blood-stained pleural effusion.

Bibby AC, Daly R, Internullo E, Edey AJ, Maskell NA.

Thorax. 2018 May;73(5):497-498. doi: 10.1136/thoraxjnl-2017-211102. Epub 2017 Nov 9. No abstract available.

PMID:
29123017
38.

Conservative Management in Traumatic Pneumothoraces: An Observational Study.

Walker SP, Barratt SL, Thompson J, Maskell NA.

Chest. 2018 Apr;153(4):946-953. doi: 10.1016/j.chest.2017.10.015. Epub 2017 Nov 15.

PMID:
29080710
39.

Biomarkers in mesothelioma.

Arnold DT, Maskell NA.

Ann Clin Biochem. 2018 Jan;55(1):49-58. doi: 10.1177/0004563217741145. Epub 2017 Nov 13. Review.

PMID:
29058958
40.

Pneumothorax management: time to improve the evidence base.

Maskell NA.

Thorax. 2017 Dec;72(12):1065-1066. doi: 10.1136/thoraxjnl-2017-211007. Epub 2017 Sep 25. No abstract available.

PMID:
28947668
41.

Randomized Controlled Trial of Urokinase versus Placebo for Nondraining Malignant Pleural Effusion.

Mishra EK, Clive AO, Wills GH, Davies HE, Stanton AE, Al-Aloul M, Hart-Thomas A, Pepperell J, Evison M, Saba T, Harrison RN, Guhan A, Callister ME, Sathyamurthy R, Rehal S, Corcoran JP, Hallifax R, Psallidas I, Russell N, Shaw R, Dobson M, Wrightson JM, West A, Lee YCG, Nunn AJ, Miller RF, Maskell NA, Rahman NM.

Am J Respir Crit Care Med. 2018 Feb 15;197(4):502-508. doi: 10.1164/rccm.201704-0809OC. Erratum in: Am J Respir Crit Care Med. 2018 Apr 15;197(8):1092-1093.

PMID:
28926296
42.

The physiological consequences of different distributions of diffuse pleural thickening on CT imaging.

de Fonseka D, Edey A, Stadon L, Viner J, Darby M, Maskell NA.

Br J Radiol. 2017 Aug;90(1077):20170218. doi: 10.1259/bjr.20170218. Epub 2017 Jul 14.

43.

A Novel Drug-Eluting Indwelling Pleural Catheter for the Management of Malignant Effusions.

Bhatnagar R, Zahan-Evans N, Kearney C, Edey AJ, Stadon LJ, Tremblay A, Maskell NA.

Am J Respir Crit Care Med. 2018 Jan 1;197(1):136-138. doi: 10.1164/rccm.201701-0097LE. No abstract available.

PMID:
28574275
44.

Prognostication and monitoring of mesothelioma using biomarkers: a systematic review.

Arnold DT, De Fonseka D, Hamilton FW, Rahman NM, Maskell NA.

Br J Cancer. 2017 Mar 14;116(6):731-741. doi: 10.1038/bjc.2017.22. Epub 2017 Feb 7. Review.

45.

The role of serum procalcitonin in establishing the diagnosis and prognosis of pleural infection.

Dixon G, Lama-Lopez A, Bintcliffe OJ, Morley AJ, Hooper CE, Maskell NA.

Respir Res. 2017 Feb 3;18(1):30. doi: 10.1186/s12931-017-0501-5.

46.

Nonmalignant Pleural Effusions: A Prospective Study of 356 Consecutive Unselected Patients.

Walker SP, Morley AJ, Stadon L, De Fonseka D, Arnold DT, Medford ARL, Maskell NA.

Chest. 2017 May;151(5):1099-1105. doi: 10.1016/j.chest.2016.12.014. Epub 2016 Dec 23.

PMID:
28025056
47.

Malignant pleural mesothelioma: an update on investigation, diagnosis and treatment.

Bibby AC, Tsim S, Kanellakis N, Ball H, Talbot DC, Blyth KG, Maskell NA, Psallidas I.

Eur Respir Rev. 2016 Dec;25(142):472-486. doi: 10.1183/16000617.0063-2016. Review.

48.

Diagnostic and Prognostic Biomarkers in the Rational Assessment of Mesothelioma (DIAPHRAGM) study: protocol of a prospective, multicentre, observational study.

Tsim S, Kelly C, Alexander L, McCormick C, Thomson F, Woodward R, Foster JE, Stobo DB, Paul J, Maskell NA, Chalmers A, Blyth KG.

BMJ Open. 2016 Nov 24;6(11):e013324. doi: 10.1136/bmjopen-2016-013324.

49.

Current best practice in the evaluation and management of malignant pleural effusions.

Walker S, Bibby AC, Maskell NA.

Ther Adv Respir Dis. 2017 Feb;11(2):105-114. doi: 10.1177/1753465816671697. Epub 2016 Oct 24. Review.

50.

Prophylactic radiotherapy to prevent procedure-tract metastases - Author's reply.

Clive AO, Taylor H, Maskell NA.

Lancet Oncol. 2016 Oct;17(10):e419. doi: 10.1016/S1470-2045(16)30454-5. No abstract available.

PMID:
27733265

Supplemental Content

Loading ...
Support Center